Subtype classification of malignant lymphoma using immunohistochemical staining pattern - Scorecard - MDSpire

Subtype classification of malignant lymphoma using immunohistochemical staining pattern

  • By

  • Noriaki Hashimoto

  • Kaho Ko

  • Tatsuya Yokota

  • Kei Kohno

  • Masato Nakaguro

  • Shigeo Nakamura

  • Ichiro Takeuchi

  • Hidekata Hontani

  • February 11, 2022

  • 0 min

Share

Clinical Scorecard: Classification of Malignant Lymphoma Subtypes Through Immunohistochemical Staining Patterns

At a Glance

CategoryDetail
ConditionMalignant lymphoma with over 70 subtypes
Key MechanismsIdentification of lymphoma subtypes via morphological features on H&E-stained tissue slides and immunohistochemical (IHC) staining patterns
Target PopulationPatients with malignant lymphoma undergoing pathological diagnosis
Care SettingPathology laboratories utilizing whole slide imaging and digital pathology analysis

Key Highlights

  • Subtype classification relies on initial H&E-stained slide observation followed by selection of IHC stains to confirm diagnosis.
  • Typicality of morphological features on H&E slides is quantitatively evaluated based on the sets of IHC stains used for definitive diagnosis.
  • Instance selection based on typicality improves generalization ability of subtype classification models using MIL-based CNNs.

Guideline-Based Recommendations

Diagnosis

  • Begin with microscopic examination of H&E-stained tissue slides to infer candidate lymphoma subtypes.
  • Select IHC stains based on initial subtype candidates to confirm definitive diagnosis.
  • Recognize that typical morphological features require fewer IHC stains, while atypical features necessitate additional stains.

Management

  • Use subtype identification to guide appropriate lymphoma treatment strategies.

Monitoring & Follow-up

  • Employ digital pathology and machine learning tools to assist in subtype classification and monitor diagnostic accuracy.

Risks

  • Potential overfitting of classification models if training data includes atypical instances without appropriate selection.
  • Misclassification risk if atypical morphological features are not adequately accounted for.

Patient & Prescribing Data

Patients diagnosed with malignant lymphoma subtypes including DLBCL, AITL, and CHL

Accurate subtype classification via typicality-based instance selection supports tailored therapeutic decisions.

Clinical Best Practices

  • Incorporate typicality evaluation of H&E-stained slides based on IHC stain sets to select training data for machine learning models.
  • Utilize MIL-based convolutional neural networks to focus on cancerous regions within whole slide images without manual annotations.
  • Recognize variability in IHC stain sets both within and between lymphoma subtypes to inform diagnostic strategies.

References

Original Source(s)

Related Content